Recoupment suits by particular payors (such as state governments) have enjoyed much success, but class actions on behalf of drug users generally seeking refunds over allegedly faulty pharmaceutical marketing are losing at the class certification stage, because questions of what would have happened with different or no marketing are too individualized. Beck and Herrmann explain.
Drug-pricing class actions falling short
- Prospective injunctive relief class actions and McNair v. Synapse Group Inc.
- Federal district court dismisses Netflix suit
- Hans Bader on challenging class-action abuses
- Wal-Mart Settlement Offer: Potentially Pocket Change for Class Member Participants
- In re Bluetooth Headset Products Liability Litigation: CCAF Ninth Circuit victory
- Bad observational humor does not equal consumer fraud claim
- Wal-Mart v. Dukes & A.E.P. v. Connecticut
- Rice Krispies class action settlement
- Around the web, May 23
- Back Doctors Ltd. v. Metropolitan Property & Cas. Ins. Co.: CAFA jurisdictional limits
- The NVIDIA class action settlement bait-and-switch
- Around the web, February 13
- Around the web, February 10
- Kabateck Brown Kellner and a figurehead plaintiff?
- Around the web, December 29